Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bendamustine
Related studies linked through entity extraction aliases.
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
- Status
- COMPLETED
- Phase
- PHASE3
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
- Status
- COMPLETED
- Phase
- PHASE1
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- Status
- TERMINATED
- Phase
- PHASE3
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1